Teton Advisors, Inc. Supernus Pharmaceuticals, Inc. Transaction History

Teton Advisors, Inc.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 13, 2022	SELL	$28.51 - $32.9 $313,610 - $361,900	-11,000 Closed	0 $0
Q1 2021 May 14, 2021	SELL	$24.15 - $31.45 $176,295 - $229,585	-7,300 Reduced 39.89%	11,000 $288,000
Q2 2020 Aug 13, 2020	SELL	$17.09 - $24.89 $46,143 - $67,203	-2,700 Reduced 12.86%	18,300 $435,000
Q4 2019 Feb 14, 2020	BUY	$19.93 - $29.13 $243,146 - $355,386	12,200 Added 138.64%	21,000 $498,000
Q3 2019 Nov 01, 2019	BUY	$25.47 - $33.37 $224,136 - $293,656	8,800 New	8,800 $242,000

255

59.2M

47.9K

13.1K

Ticker SUPN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 53,495,300
Market Cap $1.64B
Description
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...

Get notified when there are updates to the investment portfolio of Teton Advisors, Inc., based on Form 13F filings with the SEC.

Stay updated on Teton Advisors, Inc. with notifications on news.